Dr. Lal PathLabs Launches South Asia's First Advanced Amyloidosis Test

A pioneer in diagnostic medicine, Dr. Lal PathLabs Limited (Dr. Lal PathLabs) has unveiled Amyloid Typing by Laser Capture Microdissection & Mass Spectrometry, a ground-breaking test for precisely identifying various forms of amyloid proteins. Dr. Lal PathLabs is now the only diagnostic chain in South Asia to provide this extremely specialized test.

Amyloidosis is a condition in which the aberrant or misfolded amyloid protein builds up in several important organs, sometimes resulting in death. Up to this point, more than 40 different kinds of amyloid proteins have been identified; knowing the exact type of amyloid aids physicians in selecting the best course of action for a patient's care. Any organ in the body can be impacted, however the most frequently involved are the kidney, heart, lungs, and skin.Commenting on the launch, Shankha Banerjee, CEO of Dr. Lal PathLabs, said, "Our mission is to bring world-class diagnostics to India. By introducing this advanced Amyloidosis test, we aim to provide doctors with critical insights for accurate diagnosis and personalized treatment. We are proud to be the first diagnostic chain in South Asia to offer this cutting-edge solution."

This test was introduced by Dr. Lal PathLabs with assistance from the National Amyloidosis Centre in London, UK. This development reinforces Dr. Lal PathLabs' dedication to provide cutting-edge, easily accessible, and trustworthy diagnostic services throughout India.